A major pharmaceutical company announced disappointing results Monday for its experimental weight loss medication, dealing a significant blow in the competitive obesity drug marketplace.
Danish drugmaker Novo Nordisk revealed that its developing treatment CagriSema performed worse than competitor Eli Lilly’s tirzepatide when tested directly against each other in clinical studies.
The clinical study was structured to demonstrate that CagriSema could match tirzepatide’s effectiveness in helping patients lose weight, but the experimental drug failed to reach that benchmark, according to company officials.
This disappointing outcome represents a major challenge for Novo Nordisk as it attempts to reclaim its early leadership position in the profitable weight management pharmaceutical sector, where consumers increasingly demand more powerful treatments.
Following the announcement, Novo Nordisk’s stock value dropped 11% by mid-morning European trading.
According to the company’s data, CagriSema helped patients achieve a 23% reduction in body weight during the 84-week study period, while Eli Lilly’s tirzepatide produced a 25.5% weight reduction in the same trial.
These findings indicate that Novo’s developing medication was less successful than Eli Lilly’s existing treatment, which consumers can already purchase under the brand names Zepbound and Mounjaro.
Company officials noted that additional studies are currently investigating CagriSema’s complete weight reduction capabilities, including testing stronger dosage combinations.
Meanwhile, Lilly’s stock price increased 4% to $1,049.94 during pre-market trading in the United States.
